The Butantan vaccine is called “trivalent,” after its capacity to generate immune responses against three variants of the influenza virus: H1N1, the B strain, and H3N2.
The government,Health Minister Marcelo Queiroga said, plans to immunize 90 percent of the target public at approximately 38 thousand basic care stations qualified to vaccinate people across the country.
80 million doses of the trivalent influenza vaccine—produced by the Butantan Institute and effective against the H1N1, H3N2, and type B strains—will be available.
The vaccine includes ButanVac - an immunizer produced by Butantan, which is being evaluated in clinical trials, and the influenza vaccine, also produced by the institute.
The product should allow consumers to determine whether they have been infected with the novel coronavirus in just 15 minutes. The first batches should be delivered to drugstores early in March.
Português 
Español 
